Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
J Nippon Med Sch ; 91(2): 190-197, 2024.
Article in English | MEDLINE | ID: mdl-38777782

ABSTRACT

BACKGROUND: The appropriate duration of antimicrobial therapy for febrile urinary tract infection (fUTI) in children has not been established. This study examined the optimal duration of treatment for fUTI in children. METHODS: We created a protocol that used fever duration to determine the duration of antibiotic administration. Transvenous antibiotics were administered until 3 days after resolution of fever, followed by oral antibiotics for 1 week. Diagnosis of fUTI was based on a fever of 37.5°C or higher and a quantitative culture of catheterized urine yielded a bacteria count of ≥5 × 104. Acute focal bacterial nephritis (AFBN) and pyelonephritis (PN) were diagnosed on the basis of contrast-enhanced computed tomography (eCT) findings. We retrospectively reviewed treatment outcomes. RESULTS: Of the 78 patients treated according to our protocol, data from 58 were analyzed-49 children (30 boys) had PN and nine (three boys) had AFBN. Blood test results showed that patients with AFBN had significantly higher white blood cell counts and C-reactive protein levels than did those with PN; however, urinary findings and causative bacteria did not differ between groups. Time to resolution of fever and duration of intravenous antibiotic administration were significantly longer in patients with AFBN than in those with PN. However, average duration of AFBN treatment was 14.2 days, which was shorter than the previously reported administration period of 3 weeks. No recurrence was observed in AFBN patients. CONCLUSIONS: A protocol that used fever duration to determine the duration of antimicrobial treatment was useful. Invasive examinations, such as eCT, were not required.


Subject(s)
Anti-Bacterial Agents , Fever , Pyelonephritis , Urinary Tract Infections , Humans , Urinary Tract Infections/microbiology , Urinary Tract Infections/therapy , Urinary Tract Infections/drug therapy , Urinary Tract Infections/diagnosis , Male , Female , Fever/etiology , Fever/therapy , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Retrospective Studies , Child, Preschool , Time Factors , Pyelonephritis/therapy , Pyelonephritis/microbiology , Pyelonephritis/drug therapy , Infant , Child , Treatment Outcome , Tomography, X-Ray Computed , C-Reactive Protein/analysis , Nephritis/microbiology , Nephritis/therapy , Administration, Oral , Acute Disease , Duration of Therapy , Leukocyte Count , Administration, Intravenous , Clinical Protocols
2.
J Nippon Med Sch ; 90(5): 419-424, 2023 Nov 07.
Article in English | MEDLINE | ID: mdl-36273908

ABSTRACT

Trisomy 21 (Down syndrome) is sometimes complicated by congenital heart disease; however, comorbid type I diabetes mellitus and diseases involving autoantibodies, such as Hashimoto disease and Graves disease, are not uncommon. Autoinflammatory diseases such as Kawasaki disease and systemic juvenile idiopathic arthritis are rare. We report a rare case of trisomy 21 with systemic juvenile idiopathic arthritis that responded well to the initial course of methylprednisolone pulse therapy but flared up and was complicated by macrophage activation syndrome (MAS). Subsequent methylprednisolone pulse therapy and cyclosporine resolved this condition. Cytokines were analyzed at several time points during the clinical course and revealed that interleukin-18, interleukin-6, and chemokine ligand 9 levels were elevated at MAS onset in the present patient, even though clinical symptoms had abated. Thus, early analysis of cytokine profiles should be performed to assess MAS risk and determine treatment intensity, even in T21 patients.


Subject(s)
Arthritis, Juvenile , Down Syndrome , Macrophage Activation Syndrome , Humans , Arthritis, Juvenile/complications , Arthritis, Juvenile/diagnosis , Arthritis, Juvenile/drug therapy , Down Syndrome/complications , Cytokines , Macrophage Activation Syndrome/diagnosis , Macrophage Activation Syndrome/etiology , Macrophage Activation Syndrome/drug therapy , Methylprednisolone , Disease Progression
3.
Mod Rheumatol ; 33(5): 1021-1029, 2023 Aug 25.
Article in English | MEDLINE | ID: mdl-36112493

ABSTRACT

OBJECTIVES: Although epidemiological surveys of paediatric rheumatic diseases in Japan have been conducted, they were single surveys with no continuity. This is the first report of the Pediatric Rheumatology Association of Japan registry database, which was established to continuously collect data for paediatric rheumatic diseases. METHODS: Pediatric Rheumatology International Collaborate Unit Registry version 2 (PRICUREv2) is a registry database established by the Pediatric Rheumatology Association of Japan. The registry data were analysed for the age of onset, time to diagnosis, sex differences, seasonality, and other factors. RESULTS: Our data showed the same trend regarding rates of paediatric rheumatic diseases reported in Japan and other countries. The age of onset was lower in juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis and higher in systemic lupus erythematosus and Sjögren's syndrome. The time to diagnosis was relatively short in JIA and systemic lupus erythematosus but longer in juvenile dermatomyositis and Sjögren's syndrome. Rheumatoid factor-positive polyarticular JIA showed a seasonality cluster with regard to onset. CONCLUSION: PRICUREv2 aided the retrieval and evaluation of current epidemiological information on patients with paediatric rheumatic diseases. It is expected that the data collection will be continued and will be useful for expanding research in Japan.


Subject(s)
Arthritis, Juvenile , Dermatomyositis , Lupus Erythematosus, Systemic , Rheumatic Diseases , Rheumatology , Sjogren's Syndrome , Child , Humans , Male , Female , Rheumatic Diseases/epidemiology , Dermatomyositis/diagnosis , Dermatomyositis/epidemiology , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/epidemiology , Japan/epidemiology , Arthritis, Juvenile/epidemiology , Registries , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/epidemiology
4.
Mod Rheumatol Case Rep ; 7(1): 148-153, 2023 01 03.
Article in English | MEDLINE | ID: mdl-35953299

ABSTRACT

In paediatric primary Sjögren's syndrome (SS), the initial symptoms manifest systemically, such as fever, general fatigue, and lymphadenopathy, rather than sicca symptoms. Most children with primary SS have autoantibodies, such as antinuclear, anti-Ro/SS-A, and/or anti-La/SS-B antibodies; however, some patients are seronegative. Similar to paediatric patients with primary SS, those with Takayasu arteritis (TAK) initially only present constitutional symptoms, making it difficult to suspect, unless characteristic features are present. To our knowledge, there have been no reports of the coexistence of both diseases in children. We present a rare case of seronegative SS complicated by TAK in a 9-year-old girl who presented with a persistent low-grade fever, general fatigue, cervical lymphadenopathy, and multiple caries. Although blood examination revealed all autoantibodies to be negative, a lip biopsy revealed lymphocytic sialadenitis, and a sialoscintigraphy indicated hypofunctional salivary glands, leading to the diagnosis of seronegative SS. The patient was treated with low-dose glucocorticoid and immunosuppressant administration to inhibit persistent inflammation and the progression of salivary gland dysfunction; although the symptoms resolved, inflammatory markers remained elevated. When the patient was 14 years old, cervical bruits were incidentally found, and TAK was suspected based on cervical ultrasonography and magnetic resonance angiography findings. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography results demonstrated increased fluorodeoxyglucose accumulation from the ascending to descending aorta. Therefore, she was diagnosed with SS complicated by TAK, which is rare. Aortitis should be suspected when the cause of persistent inflammation cannot be ascertained in patients with SS.


Subject(s)
Lymphadenopathy , Sjogren's Syndrome , Takayasu Arteritis , Adolescent , Female , Humans , Autoantibodies , East Asian People , Fluorodeoxyglucose F18 , Inflammation/complications , Lymphadenopathy/complications , Sjogren's Syndrome/complications , Sjogren's Syndrome/diagnosis , Takayasu Arteritis/complications , Takayasu Arteritis/diagnosis , Takayasu Arteritis/drug therapy
5.
J Nippon Med Sch ; 89(2): 233-237, 2022 May 12.
Article in English | MEDLINE | ID: mdl-33692305

ABSTRACT

Clear-cell sarcoma of the kidney (CCSK) is a rare, aggressive pediatric renal tumor. Intratumoral hemorrhage and tumor rupture are oncologic emergencies requiring a rapid and appropriate response. An 11-year-old boy visited our hospital with abdominal distension of 1 month's duration. Computed tomography (CT) revealed a tumor in the left kidney (size: 200 mm), and analysis of a biopsy specimen confirmed a diagnosis of CCSK. Chemotherapy was initiated to shrink the large, densely vascularized tumor before surgical removal. Two days after starting chemotherapy, the patient developed abdominal and back pain, anemia, and hypotension. CT scanning showed intratumoral bleeding. Emergency transcatheter arterial embolization (TAE) was performed to control the bleeding. Three tumor feeding vessels were identified: an ascending branch from the celiac artery, an intermediate branch from the left renal artery, and a descending branch from the inferior mesenteric artery, of which the intermediate and descending branches were large and bleeding profusely. Therefore, the intermediate branch was injected with ethanol, and the descending branch was treated by gel-foam embolization. Chemotherapy was resumed, and the patient's condition gradually stabilized. The tumor began to shrink, and subsequent chemotherapy progressed well. In week 12 of chemotherapy, the patient underwent tumor resection and left nephrectomy. Postoperative chemotherapy was completed without complications, and there was no recurrence during a 6-year follow-up period. Therefore, TAE can effectively control intratumoral bleeding in pediatric solid tumors, thus preventing high-risk open surgery.


Subject(s)
Embolization, Therapeutic , Kidney Neoplasms , Sarcoma , Child , Embolization, Therapeutic/methods , Female , Hemorrhage/etiology , Hemorrhage/therapy , Humans , Kidney/diagnostic imaging , Kidney Neoplasms/complications , Kidney Neoplasms/therapy , Male , Renal Artery , Sarcoma/complications , Sarcoma/therapy
6.
CEN Case Rep ; 10(4): 608-613, 2021 11.
Article in English | MEDLINE | ID: mdl-34191240

ABSTRACT

IgA vasculitis (IgAV) is the most frequent form of vasculitis in childhood which classically presents with purpura of the lower extremities, joint pain or swelling and abdominal pain. Though it is a self-limiting disease, and its prognosis is generally good, glomerulonephritis is one of the most important complications. IgAV is classified as a small vessel vasculitis, and though glomerulonephritis develops in IgAV, necrotizing arteritis is rarely seen. Here, we present a case of a 13-year-old girl with IgAV, glomerulonephritis, and necrotizing arteritis in the small renal arteries. There have been only a few reports of adult cases of IgAV with necrotizing arteritis in the kidneys, but there have been no pediatric cases. Some previous reports showed a high mortality rate and implied the possibility of overlap with other vasculitides. In the current report, a rare case of IgAV is described which exhibited necrotizing arteritis rather than overlap with another vasculitis, with a relatively typical clinical course for IgAV and laboratory tests.


Subject(s)
Glomerulonephritis/etiology , IgA Vasculitis/complications , Polyarteritis Nodosa/etiology , Adolescent , Female , Glomerulonephritis/pathology , Humans , Kidney Glomerulus/ultrastructure , Polyarteritis Nodosa/pathology
7.
J Nippon Med Sch ; 87(3): 166-170, 2020 Jul 13.
Article in English | MEDLINE | ID: mdl-32238729

ABSTRACT

Hemophagocytic lymphohistiocytosis (HLH) associated with Epstein-Barr virus (EBV) infection can be self-limiting, severe/aggressive, or fatal. We report a case of EBV-HLH with persistent fever, severe pancytopenia, hypertriglyceridemia, and hypofibrinogenemia in a 4-year-old boy. Levels of plasma cytokines and chemokines were measured with a Bio-Plex system at 1, 2, 3, 4, 5, and 8 days after hospital admission. Administration of steroid and high-dose intravenous immunoglobulin (1 g/kg) did not alleviate fever or reduce cytokine production; however, after administration of etoposide (an antineoplastic agent), fever decreased immediately, the patient's general condition improved, and levels of IL-6, IL-10, IL-8, MCP-1, IFN-γ, and TNF-α declined after etoposide administration. In particular, IFN-γ production sharply declined, from 1,104.1 pg/mL to 101.5 pg/mL, and IL-6 level decreased from 229.8 pg/mL to 11.0 pg/mL, on the day after initial etoposide administration. There was no later recurrence of symptoms during treatment with dexamethasone, etoposide, and cyclosporine A. This case suggests that early etoposide administration is critical for treatment success and indicates that etoposide promptly inhibits cytokine production.


Subject(s)
Cytokines/metabolism , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/drug therapy , Etoposide/administration & dosage , Lymphohistiocytosis, Hemophagocytic/complications , Lymphohistiocytosis, Hemophagocytic/drug therapy , Child, Preschool , Epstein-Barr Virus Infections/metabolism , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunotherapy , Lymphohistiocytosis, Hemophagocytic/metabolism , Male , Treatment Outcome
8.
J Nippon Med Sch ; 86(4): 207-214, 2019 Sep 03.
Article in English | MEDLINE | ID: mdl-31061250

ABSTRACT

BACKGROUND: Therapeutic outcomes for childhood malignancy have dramatically improved. However, secondary malignancies are a major concern, as they greatly affect the quality of life of survivors. This retrospective study evaluated the cumulative incidence, clinical features, and outcomes of secondary malignancies at Nippon Medical School Hospital. METHODS: We examined data from 275 cases of primary childhood malignancy diagnosed between 1980 and 2014. Information regarding treatment of the primary malignancy, including irradiation dose, site, and cumulative dose of anticancer drugs, was assessed. We also collected data on secondary malignancy, including patient sex, age at diagnosis, malignancy site, time from primary to secondary malignancy, and outcomes. RESULTS: Secondary malignancies developed in 11 patients and included acute myeloid leukemia (AML) (4), meningioma (4), Ewing sarcoma (1), germ cell tumor (1), and malignant parotid gland tumor (1). The primary malignancies included acute lymphoblastic leukemia (ALL) (9), non-Hodgkin lymphoma (1) and brain tumor (1). In 7 of the 9 ALL patients, chemoradiotherapy was the primary treatment. The meningiomas and 1 solid tumor developed within the radiation field. All AMLs and meningiomas developed within 5 years and after 20 years, respectively, of the primary diagnosis. The 10- and 20-year cumulative incidence rates for secondary malignancy in our hospital were 1.9% and 5.8%, respectively. CONCLUSIONS: Our results revealed that the type of secondary malignancy depends on the interval after the end of treatment for primary malignancy. Meningioma, notably, develops many years after completion of primary malignancy treatment. Early detection during long-term follow-up is therefore essential.


Subject(s)
Bone Neoplasms/epidemiology , Leukemia, Myeloid, Acute/epidemiology , Meningeal Neoplasms/epidemiology , Meningioma/epidemiology , Neoplasms, Second Primary/epidemiology , Sarcoma, Ewing/epidemiology , Chemoradiotherapy , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Incidence , Infant , Male , Retrospective Studies , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...